Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2025 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

ceribell inc - CBLL

CBLL

Close Chg Chg %
21.29 0.13 0.61%

Closed Market

21.42

+0.13 (0.61%)

Volume: 206.06K

Last Updated:

Dec 24, 2025, 1:00 PM EDT

Trade Now

Company Overview: ceribell inc - CBLL

CBLL Key Data

Open

$21.25

 Day Range

21.01 - 21.65

52 Week Range

10.01 - 27.22

 Market Cap

$789.77M

Shares Outstanding

37.10M

 Public Float

22.33M

Beta

1.34

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$1.45

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

573.47K

  

CBLL Performance

1 Week
 
 1.04%
 
1 Month
 
 26.22%
 
3 Months
 
 88.39%
 
1 Year
 
 -19.02%
 
5 Years
 
 N/A
 

CBLL Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 8
Full Ratings ➔

About ceribell inc - CBLL

Ceribell, Inc. is a commercial-stage medical technology company, which engages in the provision of transforming the diagnosis and management of patients with serious neurological conditions. Its products include Point-of-Care EEG, which enables early detection and management of suspected seizure patients, promoting precise patient care and hospital-wide efficiencies, Clarity, an AI algorithm that interprets EEG in real-time, providing bedside alerts and continuous monitoring for status epilepticus, and EEG Portal, which makes it easy to remotely review EEG in real-time with pre-annotated EEG insights. The company was founded by Xing Juan Chao, Josef Parvizi, and Chris Chafe on August 29, 2014 and is headquartered in Sunnyvale, CA.

CBLL At a Glance

Ceribell, Inc.
360 North Pastoria Avenue
Sunnyvale, California 94085
Phone 1-800-436-0826 Revenue 65.44M
Industry Medical Specialties Net Income -40,455,000.00
Sector Health Technology 2024 Sales Growth 44.708%
Fiscal Year-end 12 / 2025 Employees 281
View SEC Filings

CBLL Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 14.177
Price to Book Ratio 4.853
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -19.586
Enterprise Value to Sales 11.543
Total Debt to Enterprise Value 0.029

CBLL Efficiency

Revenue/Employee 232,896.797
Income Per Employee -143,967.972
Receivables Turnover 6.016
Total Asset Turnover 0.46

CBLL Liquidity

Current Ratio 16.586
Quick Ratio 16.052
Cash Ratio 14.964

CBLL Profitability

Gross Margin 86.715
Operating Margin -60.676
Pretax Margin -61.816
Net Margin -61.816
Return on Assets -28.456
Return on Equity -35.749
Return on Total Capital -18.982
Return on Invested Capital -32.51

CBLL Capital Structure

Total Debt to Total Equity 11.487
Total Debt to Total Capital 10.304
Total Debt to Total Assets 9.742
Long-Term Debt to Equity 10.918
Long-Term Debt to Total Capital 9.793
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Ceribell Inc - CBLL

Collapse All in section
All values USD millions. 2022 2023 2024 5-year trend
Sales/Revenue
- 25.92M 45.23M 65.44M
Sales Growth
- - +74.47% +44.71%
-
Cost of Goods Sold (COGS) incl D&A
- 4.43M 7.06M 8.69M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
- 497.00K 847.00K 1.14M
Depreciation
- 352.00K 509.00K 741.00K
Amortization of Intangibles
- 145.00K 338.00K 400.00K
COGS Growth
- - +59.41% +23.11%
-
Gross Income
- 21.49M 38.16M 56.75M
Gross Income Growth
- - +77.57% +48.70%
-
Gross Profit Margin
- +82.91% +84.38% +86.72%
2022 2023 2024 5-year trend
SG&A Expense
- 57.51M 68.20M 96.46M
Research & Development
- 7.24M 8.99M 13.56M
Other SG&A
- 50.27M 59.21M 82.90M
SGA Growth
- - +18.59% +41.43%
-
Other Operating Expense
- - - -
-
Unusual Expense
- 175.00K (48.00K) 1.50M
EBIT after Unusual Expense
- (36.20M) (29.99M) (41.21M)
Non Operating Income/Expense
- 637.00K 2.64M 2.74M
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- 1.60M 2.10M 1.99M
Interest Expense Growth
- - +30.88% -5.05%
-
Gross Interest Expense
- 1.60M 2.10M 1.99M
Interest Capitalized
- - - -
-
Pretax Income
- (37.16M) (29.45M) (40.45M)
Pretax Income Growth
- - +20.74% -37.35%
-
Pretax Margin
- -143.36% -65.13% -61.82%
Income Tax
- - 2.00K 11.00K
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
- (37.16M) (29.46M) (40.45M)
Minority Interest Expense
- - - -
-
Net Income
- (37.16M) (29.46M) (40.45M)
Net Income Growth
- - +20.72% -37.30%
-
Net Margin Growth
- -143.37% -65.15% -61.82%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
- (37.16M) (29.46M) (40.45M)
Preferred Dividends
- - - -
-
Net Income Available to Common
- (37.16M) (29.46M) (40.45M)
EPS (Basic)
- -1.0925 -0.8661 -1.1284
EPS (Basic) Growth
- - +20.72% -30.29%
-
Basic Shares Outstanding
- 34.02M 34.02M 35.85M
EPS (Diluted)
- -1.0925 -0.8661 -1.1284
EPS (Diluted) Growth
- - +20.72% -30.29%
-
Diluted Shares Outstanding
- 34.02M 34.02M 35.85M
EBITDA
- (35.52M) (29.19M) (38.57M)
EBITDA Growth
- - +17.82% -32.11%
-
EBITDA Margin
- -137.04% -64.55% -58.93%

Snapshot

Average Recommendation BUY Average Target Price 28.00
Number of Ratings 8 Current Quarters Estimate -0.413
FY Report Date 12 / 2025 Current Year's Estimate -1.506
Last Quarter’s Earnings -0.37 Median PE on CY Estimate N/A
Year Ago Earnings -3.39 Next Fiscal Year Estimate -1.461
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 8 6 8 8
Mean Estimate -0.41 -0.38 -1.51 -1.46
High Estimates -0.35 -0.33 -1.45 -1.33
Low Estimate -0.48 -0.44 -1.58 -1.62
Coefficient of Variance -9.05 -9.89 -2.50 -8.94

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 8 8 7
OVERWEIGHT 0 0 0
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Ceribell Inc - CBLL

Date Name Shares Transaction Value
Dec 12, 2025 William W. Burke Director 27,119 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $2.26 per share 61,288.94
Dec 12, 2025 William W. Burke Director 17,391 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $22.02 per share 382,949.82
Dec 12, 2025 William W. Burke Director 40,391 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $4.7 per share 189,837.70
Dec 12, 2025 William W. Burke Director 17,391 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $22.02 per share 382,949.82
Dec 12, 2025 William W. Burke Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Dec 12, 2025 William W. Burke Director 25,151 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Dec 5, 2025 Rebecca B. Robertson Director 8,388 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $16.67 per share 139,827.96
Dec 4, 2025 Xing Juan Chao President and CEO; Director 798,135 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $16.59 per share 13,241,059.65
Dec 4, 2025 Raymond Woo Chief Technology Officer 52,138 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Dec 4, 2025 Raymond Woo Chief Technology Officer 47,821 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Dec 4, 2025 Raymond Woo Chief Technology Officer 15,746 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Dec 4, 2025 Raymond Woo Chief Technology Officer 167,704 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $12.28 per share 2,059,405.12
Dec 4, 2025 Raymond Woo Chief Technology Officer 178,816 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $4.7 per share 840,435.20
Dec 4, 2025 Raymond Woo Chief Technology Officer 172,201 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $4.7 per share 809,344.70
Dec 4, 2025 Raymond Woo Chief Technology Officer 169,176 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $2.24 per share 378,954.24
Dec 4, 2025 Xing Juan Chao President and CEO; Director 232,100 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Dec 4, 2025 Xing Juan Chao President and CEO; Director 823,135 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $3.65 per share 3,004,442.75
Apr 4, 2025 Xing Juan Chao President and CEO; Director 151,582 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 4, 2025 Scott Blumberg Chief Financial Officer 51,159 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 4, 2025 Scott Blumberg Chief Financial Officer 120,061 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Ceribell Inc in the News